Evidence map›Paper›PMID 38559768›Full record

ArticleFrontiers in plant science2024

MucoRice-CTB line 19A, a new marker-free transgenic rice-based cholera vaccine produced in an LED-based hydroponic system.

Yoshikazu Yuki, Shiho Kurokawa, Kotomi Sugiura, Koji Kashima, Shinichi Maruyama, Tomoyuki Yamanoue, Ayaka Honma, Mio Mejima, Natsumi Takeyama, Masaharu Kuroda and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in plant science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 2 countries.

Yoshikazu YukiDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Shiho KurokawaDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kotomi SugiuraDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Koji KashimaTechnical Research Institute, Asahi Kogyosha Co., Ltd., Tokyo, Japan.
Shinichi MaruyamaTechnical Research Institute, Asahi Kogyosha Co., Ltd., Tokyo, Japan.
Tomoyuki YamanoueDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Ayaka HonmaDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Mio MejimaDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Natsumi TakeyamaDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Masaharu KurodaDivision of Genome Editing Research, National Agriculture and Food Research Organization, Tsukuba, Japan.
Hiroko Kozuka-HataMedical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Masaaki OyamaMedical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Takehiro MasumuraLaboratory of Genetic Engineering, Graduate School of Agriculture, Kyoto Prefectural University, Kyoto, Japan.
Rika Nakahashi-OuchidaDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kohtaro FujihashiDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Takashi HiraizumiTechnical Research Institute, Asahi Kogyosha Co., Ltd., Tokyo, Japan.
Eiji GotoGraduate School of Horticulture, Chiba University, Chiba, Japan.
Hiroshi KiyonoDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
The University of Tokyo · JPChiba University Hospital · JPTokyo Ohka Kogyo (Japan) · JPChiba University · JPEiken Chemical (Japan) · JPHankyu Hanshin Holdings (Japan) · JPKyoto Prefectural University · JPNational Agriculture and Food Research Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously established the selection-marker-free rice-based oral cholera vaccine (MucoRice-CTB) line 51A for human use by

Indexed as

choleraMucoRiceoral vaccinerice-based vaccinevaccine development

Identifiers

PMID38559768
PMCPMC10978600
OpenAlexW4392859472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.